Survodutide (BI 456906) is a once-weekly glucagon/GLP-1 receptor dual agonist from Boehringer Ingelheim and Zealand Pharma. The GLP-1 arm curbs appetite; the glucagon arm raises energy expenditure and drives hepatic fat clearance — the feature that has made it a talking point beyond the usual weight-loss numbers. A cluster of phase 3 readouts presented at the American Diabetes Association's 2026 Scientific Sessions is behind the recent spike in attention.
In SYNCHRONIZE-1, adults with obesity lost up to 16.6% of body weight at 76 weeks versus 3.2% on placebo. A pre-specified analysis reported a 34% relative reduction in visceral fat and a 63.1% reduction in liver fat, with lean tissue accounting for no more than about 11% of total tissue-mass change at the top dose.
In SYNCHRONIZE-MASLD, in people with metabolic dysfunction-associated steatotic liver disease, 84.2% of survodutide-treated participants achieved at least a 30% relative liver-fat reduction versus 24.3% on placebo, and 61% reached normal liver-fat content (under 5%) versus 5.7% on placebo, alongside 12.2% weight loss versus 1.0%.
Tolerability followed the class pattern. GI events were the most common adverse effects, mostly mild-to-moderate during dose escalation, but discontinuation for GI reasons reached 19% of survodutide patients versus 2.9% on placebo — a higher dropout rate than the leading GLP-1 mono-agonists.
The honest trade-off: the glucagon component appears to translate into outsized liver-fat and visceral-fat effects, which matters for the separate MASH fibrosis program (LIVERAGE) where survodutide holds FDA Breakthrough Therapy designation. But weight loss sits below the triple-agonist and combination front-runners, and the GI-driven discontinuation rate is a real cost. These are obesity and MASLD trial data, not an approval.